ArticleWorld journal of gastrointestinal oncology2026
Clinical characteristics of programmed death-1 inhibitors for older patients with advanced pancreatic cancer.
Article in World journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lactate-to-albumin ratio, C-reactive protein-to-albumin ratio, and prognostic nutritional index in acute and critical care: A focused mini-review.World journal of critical care medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic cancer (PC), a highly malignant gastrointestinal cancer, is generally diagnosed at an advanced stage. However, traditional therapies for advanced PC are limited and often unsuitable for older patients.
aimTo identify clinical predictors in older patients with advanced PC to facilitate individualized treatment.
methodsThis was a retrospective clinical analysis involving 99 patients aged ≥ 65 years with advanced PC who received programmed death-1 (PD-1) inhibitors at Ningbo Medical Center Lihuili Hospital from January 2019 to January 2025. Univariate and multivariate analyses were conducted to identify clinical predictors for survival outcomes, utilizing blood levels and other clinical information.
resultsThe median progression-free survival (PFS) was 4.6 months [95% confidence interval (CI): 3.700-5.800], and the median overall survival (OS) was 6.5 months (95%CI: 5.700-8.200). Multivariate analysis helped identify meaningful clinical differences in PFS and OS across subgroups, including factors such as Eastern Cooperative Oncology Group performance status, prognostic nutritional index, and triglyceride levels. Univariate analysis showed that factors such as the location of primary PC, carbohydrate antigen 199 levels, systemic immune-inflammation, neutrophil-to-lymphocyte ratio, and the combination therapy comprising PD-1 inhibitors and radiotherapy are of significant clinical relevance to both PFS and OS.
conclusionThe treatment of advanced PC with PD-1 inhibitors presented several potential independent clinical predictive indicators of survival outcomes in older patients. This study highlighted the importance of pre-treatment clinical characteristics and hematological variables for predicting treatment outcomes in older patients with PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.